Every 10-Q that Vir Biotechnology, Inc. (VIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by a new collaboration with Astellas. Total revenues were $238,946 thousand, up from $1,214 thousand a year earlier, as the company recognized $239.3 million of license and collaboration revenue from the VIR‑5500 Astellas agreement. Net income reached $80,080, compared with a net loss of $110,958 in the prior‑year quarter, or $0.47 diluted earnings per share.
Research and development expenses rose to $135,283 thousand as Vir advanced its hepatitis delta ECLIPSE registrational program and multiple PRO‑XTEN dual‑masked T‑cell engager trials. A February 2026 follow‑on offering raised approximately $162.2 million, contributing to about $1.01 billion in cash, cash equivalents and investments as of June 30, 2026, which management believes is sufficient to fund operations for at least twelve months. Despite the profitable quarter, the company recorded a six‑month net loss of $45,615 while continuing to invest heavily in its infectious disease and oncology pipeline.
Vir Biotechnology, Inc. reported a net loss of $125.7 million for the quarter ended March 31, 2026, compared with a $121.0 million loss a year earlier, as it continued heavy investment in hepatitis delta and oncology programs. Total revenue was minimal at $(29) thousand, reflecting lower grant and collaboration activity.
Research and development spending was $108.9 million, driven by manufacturing and clinical costs for the ECLIPSE hepatitis delta program and dual-masked T-cell engagers. Cash, cash equivalents and investments totaled $809.3 million, helped by $162.3 million of net proceeds from a February follow-on equity offering. After quarter-end, Vir closed a major collaboration with Astellas around prostate cancer candidate VIR-5500, including a $240 million upfront payment and a $75 million equity investment.
Vir Biotechnology (VIR) reported Q3 2025 results with total revenue of $0.24 million and a net loss of $163.1 million (loss per share $1.17). Year-to-date, the company recorded a net loss of $395.1 million and used $365.9 million in operating cash.
Liquidity remained strong with $810.7 million in cash, cash equivalents and investments as of September 30, 2025, which management states is sufficient for at least twelve months. Q3 operating expenses totaled $173.7 million, driven by R&D of $151.5 million and SG&A of $22.2 million. The quarter included a $75.0 million milestone payment related to the Sanofi PRO-XTEN license; earlier in 2025, Vir paid $30.0 million under the restated Alnylam agreement and achieved a $17.5 million clinical milestone tied to tobevibart.
Clinical programs advanced: the ECLIPSE registrational program for chronic hepatitis delta has all trials underway, with ECLIPSE 1 enrollment completed ahead of plan and topline readouts for ECLIPSE 1–3 expected in Q1 2027. Oncology TCEs (VIR-5500, VIR-5818, VIR-5525) are in phase 1, with the first patient for VIR-5525 dosed in July 2025. Shares outstanding were 139,125,032 as of October 29, 2025.